Anavex Life Sciences (AVXL) Debt Ratio (2011)
Anavex Life Sciences recorded quarterly Debt Ratio of 0.33 in Q3 2011.
Anavex Life Sciences' Debt Ratio history runs 1 years deep, the most recent figure standing at 0.33 for Q3 2011.
- In Q3 2011, Debt Ratio changed N/A year-over-year to 0.33; the TTM figure through Sep 2011 stood at 0.33 (changed N/A YoY), while the FY2011 annual figure was 0.33, changed N/A from the prior year.
- Debt Ratio came in at 0.33 for Q3 2011 at Anavex Life Sciences.
- In the past five years, Debt Ratio ranged from a high of 0.33 in Q3 2011 to a low of 0.33 in Q3 2011.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt Ratio (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 0.18 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 1.41 |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 0.05 |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Anavex Life Sciences | 266.20 Mn | 134.45 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2011 | 0.33 |